The Supreme Court of Oklahoma ruled that Johnson & Johnson cannot be held liable for the state’s opioid crisis; a trial found the psychedelic drug psilocybin may be a highly efficacious therapy for treatment-resistant depression; people who went to bed at midnight or later had a 25% greater risk of cardiovascular disease.
In a 5-to-1 decision, the Supreme Court of Oklahoma found Johnson & Johnson cannot be held liable for the state’s opioid crisis, NPR reported. This tosses out a 2019 ruling that the company created a “public nuisance” through its marketing of prescription pain pills, as it was called in a legal argument. According to a Johnson & Johnson statement sent to NPR, “the Oklahoma State Supreme Court...rejected the misguided and unprecedented expansion of the public nuisance law as a means to regulate the manufacture, marketing, and sale of products, including the Company's prescription opioid medications.” This ruling comes weeks after other drug companies were found not liable and drug overdoses and deaths continue to increase.
The psychedelic drug psilocybin was found to be highly efficacious as a therapy for treatment-resistant depression, STAT News reported. According to a news release from Compass Pathways, the “groundbreaking” clinical trial of COMP360 psilocybin therapy found that a 25-mg dose of the drug showed a highly statistically significant and clinically relevant reduction in depressive symptom severity after 3 weeks. The study enrolled 233 participants and found that 29.1% of patients in the highest-dose group were in remission 3 weeks after treatment, whereas only 7.6% of participants who were given a 1-mg dose were in remission at that time. More than a quarter of those who received the 25-mg dose were still in remission 3 months after treatment.
A report published in European Heart Journal Digital Health found that cardiovascular events incidents were lowest in people who fell asleep between 10 and 11 PM, NBC News reported. The report further explained that falling asleep before 10 PM and after 11 PM was linked with a 24% and 12% increased risk of cardiovascular disease, respectively. Those who went to bed at midnight or later had the greatest risk at 25%. The study followed up with more than 88,000 adults for nearly 6 years, with 3.6% of participants having experienced cardiovascular events. Experts said these findings should be taken with a grain of salt, as the research shows a correlation and not a causation.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More